This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Mursla Bio

Profile

Mursla (Cambridge, UK) is an emergent techbio startup, leveraging extracellular vesicle biology to deliver nextgen multi-omics liquid biopsy tests.

Its first product is a blood test to significantly improve the early detection of liver cancer among high-risk populations so that more patients can benefit from curative treatments (surgery/transplant).

Its test is first-in-class and is differentiated from first generation liquid biopsy blood tests using circulating free DNA since it is tissue-specific, multi-omics and offers real time snapshot of disease biology.

Mursla was selected as UK Life Sciences Innovator 2023 in the Diagnostics and Precision Medicine category.